GlassScriptPhysician profile
Thomas J Zaydon
NPI 1265428809
$2,790.84
in general payments reported to CMS, 2019-2025
14 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what 76% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $25.17 · 2021: $239 · 2022: $40.24 · 2023: $520 · 2024: $171 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160 · Travel and Lodging: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,159.80 |
| Travel and Lodging | $806.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,023.98 | 2025 | |
| Abbvie INC. | $595.46 | 2023-2024 | Botox |
| Allergan, INC. | $260.31 | 2019-2022 | |
| Acelrx Pharmaceuticals, INC. | $198.95 | 2021 | |
| Sientra, INC. | $141.68 | 2019 | |
| Organogenesis INC. | $127.96 | 2023-2025 | Cygnus Dual, Puraply |
| Baxter Healthcare | $104.80 | 2025 | |
| Axogen | $103.59 | 2019 | |
| Biopro, INC. | $66.67 | 2019 | |
| Aroa Biosurgery Incorporated | $46.67 | 2024-2025 | |
| Kerecis Limited | $45.50 | 2021-2025 | Kerecis Surgiclose, Kerecis Omega3 Surgiclose, Kerecis Graftguide |
| Tela Bio, INC. | $37.25 | 2020-2021 | |
| Kci USA, INC. | $24.60 | 2023 | V.A.C. Veraflo Cleanse Choice, Prevena |
| Stryker Corporation | $13.42 | 2024 | Spy-Phi System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Zaydon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.